Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 277

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 277
---
 Proposal 6. A failure to vote, an abstention or a broker non -vote, if any, will have the same effect as a vote “AGAINST” Proposal 6. THE NLS BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE
“FOR” PROPOSAL 6. 115 APPROVAL OF THE TRANSFER AND VOTING RIGHTS LIMITATION OF 9.99%, GRANTING THE BOARD DISCRETION TO PROVIDE FOR EXCEPTIONS (ARTICLE 6 OF THE ARTICLES) (PROPOSAL 7) Due to the transactions contemplated by and in connection with the Merger, a limitation on exercisable voting rights is intended to be introduced in the Company’s articles of association. Accordingly, shareholders shall only be able to (directly or indirectly) hold, and exercise voting rights for, a maximum of 9.99% of the share capital of the Company at any one time. To effect this, the provisions on the entry of shareholders into the share register as well as the provisions on the voting rights is intended to be amended. This amendment ensures that no sole shareholder may gain a controlling voting majority in the Company without the Board of Directors (indirectly) approving such majority by approving the relevant entry of such a shareholder in the share register. The Board of Directors is of the opinion that such a limitation is in the best interest of the Company. To approve Proposal7, a resolution passed by a Supermajority Vote is required. You may vote “FOR,” “AGAINST” or “ABSTAIN” on Proposal 7. A failure to vote, an abstention or a broker non -vote, if any, will have the same effect as a vote “AGAINST” Proposal 7. THE NLS BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE
“FOR” PROPOSAL 7. 116 APPROVAL OF AMENDMENT TO THE ARTICLES TO CHANGE THE COMPANY NAME (PROPOSAL 8) At the extraordinary shareholders’ meeting, shareholders will be asked to approve the change of name of NLS from NLS Pharmaceutics Ltd. (Swiss name: NLS Pharmaceuticals AG) to “NewcelX Ltd.” (Swiss name: “NewcelX AG” and “NewcelX SA”), effective from the Effective Time. We seek the name change to reflect that the prior business has changed its business focus. Our new name shows the new emphasis of our Company on stem cell therapies. We